[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amoxicillin-clavulanate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amoxicillin-clavulanate":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,68],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100548887",false,"NCT06426836","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation","PADECMO","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit or cardiac intensive care unit\n* patient age : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n* extracorporeal membrane oxygenation circuit\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics and ciprofloxacin","ALL","15 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).",[26,27,28,29,30,31,32,33,34],"Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Cefazolin","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin","RECRUITING","2026-01-15",{"date":38,"type":39},"2026-01-16","ACTUAL",{"date":41,"type":39},"2016-08-19",{"date":43,"type":20},"2026-07-01",{"name":45,"class":46},"University Hospital, Ghent","OTHER",{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100244176","NCT02456974","Antibiotic Dosing in Pediatric Intensive Care","ADIC","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit\n* patient age\u002Fweight : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides\n* extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )","1 Day","16 Years",{"count":56,"type":20},640,"3 Days","OBSERVATIONAL","Pharmacokinetics of antibiotics in critically ill neonates, infants and children",[26,27,28,32,31,29,33,34],{"date":38,"type":39},{"date":63,"type":4},"2012-05",{"date":65,"type":20},"2027-09-01",{"name":45,"class":46},1,{"id":69,"slug":4,"hasResults":10,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":10,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":67},"100587539","NCT06929702","Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","Early Model-Informed Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children: Big Solution for Small People?","MOMENTUM","Inclusion Criteria:\n\n* Subject aged between 0 - 17 years 10 months.\n* Subject admitted to a participating ward unit (Neonatal Intensive Care Unit, Pediatric Intensive Care Unit, Pediatric Hematology-Oncology unit).\n* Strongly suspected or confirmed systemic infection.\n* Subject planned to start on intravenous amoxicillin-clavulanic acid, piperacillin-tazobactam or meropenem treatment at least aimed for a minimum duration of two days at time of inclusion. If the subject was previously treated with the same beta-lactam, the minimum interval to the previous beta-lactam treatment episode is\n* 40 hours for amoxicillin-clavulanic acid (based on elimination half-life)\n* 8 hours for piperacillin-tazobactam and meropenem (based on elimination half-life) Subject planned to start on intravenous amoxicillin (without clavulanic acid) will not be included.\n* Informed consent\u002Fassent signed by parents or legal representatives of the subject.\n* Not previously enrolled in this trial.\n\nExclusion Criteria:\n\n* Subject with serum creatinine level ≥ 2 mg\u002FL at inclusion.\n* Subject receiving (or planned to receive) haemofiltration, extracorporeal membrane oxygenation, hemodialysis or peritoneal dialysis, molecular adsorbent recirculating system or any other exchange technique.\n* Subject receiving (or planned to receive) body cooling.\n* Subject death is deemed imminent and inevitable.\n* Reporting of first dosing advice (based on blood sampling) is not possible within 28 hours (\\*) after start treatment.\n* The subject is known or suspected to be pregnant.\n* The subject has a known allergy to the specific beta-lactam antibiotic.\n\n(\\*) The first (a posteriori) dose calculation and dose adjustment if necessary, is performed within a maximum timeframe of 28 hours after start of treatment (i.e. maximum timeframe to first dose adjustment).","0 Years","18 Years",{"count":78,"type":20},58,[80],"PHASE4","The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem) in critically ill children. This evaluation includes a comparison with the more standard approach on clinical and patient-oriented measures.",[27,28,29],[84,85,86,87,88,89],"amoxicillin-clavulanate","piperacillint-tazobactam","meropenem","model-informed precision dosing","dose calculator","critically ill children","NOT_YET_RECRUITING","2025-04-08",{"date":93,"type":39},"2025-04-16",{"date":95,"type":20},"2025-04-22",{"date":97,"type":20},"2027-10-01",{"name":45,"class":46},""]